Symptomatic carotid plaques show a distinct cellular shift toward injury and remodeling
Human carotid atherosclerotic plaques with symptoms carry a different molecular fingerprint than asymptomatic lesions, and the difference appears to live inside the vessel wall itself. In a preprint analysis of 53 plaques, investigators combined single-nucleus RNA sequencing from 17 samples with single-cell RNA sequencing from 36 samples drawn from public datasets to compare symptomatic and asymptomatic disease at cellular resolution.
The study is centered on a simple clinical problem with high stakes: why do some plaques remain silent while others rupture or shed embolic material and trigger ischemic events? The answer here is not a single pathway, but a coordinated change across smooth muscle cells, endothelial cells, fibroblasts, and T cells. Symptomatic plaques shifted toward later or terminal states in osteochondrogenic smooth muscle cells and CD4⁺ T cells, while endothelial cells, T cells, and fibroblasts displayed transcriptional programs linked to inflammation and epithelial-to-mesenchymal transition.
One striking finding came from the nuclear dataset. Fibroblasts were depleted in symptomatic plaques, with downregulation of RGS5 marking that loss. In practical terms, fewer fibroblast-like stromal cells and more advanced remodeling states may leave the plaque structure less stable and more prone to symptomatic transformation. The signal fits the pathology of vulnerability: a lesion that has crossed from chronic buildup into an actively reorganizing, inflamed, and structurally stressed state.
Vascular wall cells carried the strongest genetic signal
The transcriptomic changes became more interesting once the investigators overlaid them with genome-wide association data for coronary, cerebrovascular, and peripheral atherosclerotic disease. Genetic risk clustered mainly in vascular wall cells—smooth muscle cells, fibroblasts, and endothelial cells—rather than in immune cells. That pattern matters because it points away from a purely leukocyte-driven model of plaque instability and toward a broader tissue-level failure involving the scaffold, lining, and contractile elements of the artery.
Symptomatic plaque biology often gets framed around macrophages and inflammation, yet these data suggest that the wall cells themselves may be the more faithful record of inherited susceptibility. Endothelial dysfunction can amplify leukocyte adhesion, reduce barrier integrity, and promote a pro-migratory phenotype. Smooth muscle cells can abandon their contractile identity and move into osteochondrogenic or other terminal states, weakening the fibrous cap and altering plaque mechanics. Fibroblasts, when depleted or transcriptionally altered, may contribute less to matrix maintenance and repair.
The study did not stop at broad enrichment. It also nominated several candidate driver mechanisms that could bridge genetic risk and symptomatic plaque transition. Higher TWIST1 expression in endothelial cells colocalized with risk across four atherosclerotic phenotypes. Lower GUCY1A1 expression in fibroblasts and macrophages, and higher MRAS expression in T cells, emerged as additional candidates. Each of these genes sits in a biologically credible position: endothelial regulation, nitric oxide signaling, matrix-related stromal behavior, and lymphocyte activation all intersect with the mechanics of plaque rupture.
Endothelial and immune programs converged on inflammation and EMT
The most consistent transcriptional theme across sequencing approaches was a move toward inflammation and epithelial-to-mesenchymal transition-like behavior in endothelial cells, T cells, and fibroblasts. In atherosclerosis, endothelial plasticity is not a side issue. Endothelial cells regulate permeability, thrombogenicity, and inflammatory trafficking, so a shift into a mesenchymal-like or activated state can reshape the plaque surface and the cells below it.
CD4⁺ T cells also showed a transition toward later or terminal states in symptomatic plaques. That observation aligns with the notion that adaptive immune activity becomes more fixed and differentiated as plaque disease advances. Rather than a transient inflammatory response, the plaque may host a sustained immunologic program that reinforces local injury and remodeling.
Atherosclerotic plaque vulnerability is often described through cap thickness, necrotic core size, and macrophage burden. Those features remain clinically relevant, but this analysis adds a more granular view: symptomatic plaques appear to be ecosystems in which vascular wall cells are transcriptionally reprogrammed while immune cells participate in a more advanced inflammatory state. The biology is layered, not linear.
What the preprint adds to plaque biology and therapeutic targeting
This work offers a cellular map of symptomatic atherosclerosis that could inform future therapeutic development. If vascular wall cells carry much of the genetic liability, then the most actionable targets may not always sit in classical immune pathways. Endothelial signaling, smooth muscle cell fate, and fibroblast maintenance may be equally important levers for keeping plaques stable.
The candidate genes carry different implications. TWIST1 in endothelial cells points toward transcriptional control of cell-state changes. GUCY1A1 suggests altered nitric oxide-cGMP signaling, a pathway central to vascular tone and endothelial function. MRAS in T cells raises the possibility that T-cell activation and survival programs also contribute to the transition from silent disease to symptomatic plaque.
Because the work combines snRNA-seq and scRNA-seq, it strengthens the impression that these are not artifacts of one platform alone. The repeated appearance of related cellular states across sequencing methods makes the plaque phenotype look robust rather than incidental. Still, this remains a preprint, and the findings have not undergone peer review. The data are compelling, but they are not yet a basis for changing clinical care.
Why the biology matters at the bedside
Symptomatic carotid atherosclerosis is not only an anatomic disease; it is a dynamic tissue disorder. A plaque that has lost fibroblast support, shifted smooth muscle cells into later states, and accumulated endothelial inflammatory programming is biologically primed for instability. The study’s main contribution is to make that instability visible at the level of single cells and candidate genes.
What remains unresolved is how these molecular states map onto timing, risk stratification, and eventual treatment selection in individual patients. The analysis identifies plausible mechanisms, not validated diagnostic markers or treatment targets. Larger validation cohorts, functional experiments, and prospective clinical correlation will be needed before these cellular signatures can be translated into routine vascular decision-making.